The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada

NCT01105507 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

4

Enrollment

INDUSTRY

Sponsor class

Conditions

Cryopyrin Associated Periodic Syndrome

Interventions

DRUG: canakinumab (company code: ACZ885D)

Sponsor

Novartis Pharmaceuticals